Qventus, Inc

qventus.com

Qventus’ mission is to simplify how healthcare operates so it just works — for everyone. The company offers an AI-based software platform that helps hospital teams make better operational decisions in real-time. Qventus addresses operational challenges across the hospital including emergency departments, perioperative areas, patient safety, in-patient, outpatient and pharmacy. Located in Silicon Valley, Qventus is honored to be working with leading public, academic and community hospitals across the United States.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

GINKGO BIOWORKS ADVANCES COLLABORATION WITH NOVO NORDISK ON EXPRESSION SYSTEMS FOR PHARMACEUTICAL PRODUCTS

PRNewswire | July 13, 2023

news image

Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity, today announced the completion of the pilot phase of their previously announced partnership with Novo Nordisk, a leading global healthcare company, to develop expression systems for pharmaceutical products. With the pilot phase completed and the first milestone achieved, the two companies will now move into the development phase to work towards making a more effective production process. Achievemen...

Read More

Research

RHYTHM PHARMACEUTICALS RECEIVES FDA APPROVAL FOR OBESITY MED TARGETING GENETIC DEFECTS

Rhythm | December 01, 2020

news image

Stoutness is a significant issue around the world, in any case, for a small amount of patients, hereditary changes instead of propensities are driving the sickness. With its new FDA endorsement for Imcivree, Rhythm Pharmaceuticals is venturing out treating those cases. For a subset of heftiness patients, hereditary transformations leave them with an "voracious appetite," Rhythm CEO David Meeker, M.D., said in a meeting. Beginning stage hereditary illnesses can leave pati...

Read More

Business Insights

TELIX PHARMACEUTICALS ANNOUNCES LICENCE AGREEMENT WITH LILLY FOR OLARATUMAB

Telix Pharmaceuticals Limited | April 11, 2022

news image

Telix Pharmaceuticals Limited announces that it has entered into a licence agreement with Eli Lilly and Company under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers. Telix's initial development focus will be on a rare type of cancer known as soft tissue sarcoma. Olaratumab was originally developed by Lilly as a monoclonal antibody targeting Pl...

Read More

Pharmacy Market

IAMA THERAPEUTICS PARTNERS WITH THE ITALIAN INSTITUTE OF TECHNOLOGY TO EMBARK ON LANDMARK RESEARCH ON NEUROSCIENCE DRUG DISCOVERY

IAMA Therapeutics | March 31, 2022

news image

IAMA Therapeutics, a Series A preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, today announced a strategic collaboration with the IIT-Istituto Italiano di Tecnologia where they will design and profile new classes of compounds targeting cation cotransporters in the CNS area. This partnership consolidates a scientific collaboration ...

Read More
news image

Pharmacy Market

GINKGO BIOWORKS ADVANCES COLLABORATION WITH NOVO NORDISK ON EXPRESSION SYSTEMS FOR PHARMACEUTICAL PRODUCTS

PRNewswire | July 13, 2023

Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity, today announced the completion of the pilot phase of their previously announced partnership with Novo Nordisk, a leading global healthcare company, to develop expression systems for pharmaceutical products. With the pilot phase completed and the first milestone achieved, the two companies will now move into the development phase to work towards making a more effective production process. Achievemen...

Read More
news image

Research

RHYTHM PHARMACEUTICALS RECEIVES FDA APPROVAL FOR OBESITY MED TARGETING GENETIC DEFECTS

Rhythm | December 01, 2020

Stoutness is a significant issue around the world, in any case, for a small amount of patients, hereditary changes instead of propensities are driving the sickness. With its new FDA endorsement for Imcivree, Rhythm Pharmaceuticals is venturing out treating those cases. For a subset of heftiness patients, hereditary transformations leave them with an "voracious appetite," Rhythm CEO David Meeker, M.D., said in a meeting. Beginning stage hereditary illnesses can leave pati...

Read More
news image

Business Insights

TELIX PHARMACEUTICALS ANNOUNCES LICENCE AGREEMENT WITH LILLY FOR OLARATUMAB

Telix Pharmaceuticals Limited | April 11, 2022

Telix Pharmaceuticals Limited announces that it has entered into a licence agreement with Eli Lilly and Company under which Telix is granted exclusive worldwide rights to develop and commercialise radiolabelled forms of Lilly's olaratumab antibody for the diagnosis and treatment of human cancers. Telix's initial development focus will be on a rare type of cancer known as soft tissue sarcoma. Olaratumab was originally developed by Lilly as a monoclonal antibody targeting Pl...

Read More
news image

Pharmacy Market

IAMA THERAPEUTICS PARTNERS WITH THE ITALIAN INSTITUTE OF TECHNOLOGY TO EMBARK ON LANDMARK RESEARCH ON NEUROSCIENCE DRUG DISCOVERY

IAMA Therapeutics | March 31, 2022

IAMA Therapeutics, a Series A preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, today announced a strategic collaboration with the IIT-Istituto Italiano di Tecnologia where they will design and profile new classes of compounds targeting cation cotransporters in the CNS area. This partnership consolidates a scientific collaboration ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us